Dogansen, Sema Ciftci <br/><br/>
Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?  [electronic resource] 

 -  Pituitary  Jun 2016 
 - 303-10 p.  digital 
<br/><br/> Publication Type: Journal Article; Observational Study 
<br/><br/><label>ISSN: </label>1573-7403 
<br/><br/><label>Standard No.: </label>10.1007/s11102-016-0708-3  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Bromocriptine--administration & dosage<br/>Cabergoline<br/>Deprescriptions<br/>Dopamine Agonists--administration & dosage<br/>Ergolines--administration & dosage<br/>Female<br/>Humans<br/>Hyperprolactinemia--blood<br/>Male<br/>Middle Aged<br/>Neoplasm Recurrence, Local--blood<br/>Patient Selection<br/>Pituitary Neoplasms--blood<br/>Prolactin--blood<br/>Prolactinoma--blood<br/>Retrospective Studies<br/>Time Factors<br/>Tumor Burden<br/>Young Adult